Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
Lung Cancer (Amsterdam, Netherlands)
|
January 2, 2021
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
Filippo de Marinis, Konstantin K Laktionov, Artem Poltoratskiy, et al.
Pathology Oncology Research : POR
|
January 10, 2022
Increase in the Length of Lung Cancer Patient Pathway Before First-Line Therapy: A 6-Year Nationwide Analysis From Hungary
Zoltan Kiss, Krisztina Bogos, Lilla Tamási, et al.
Pathology Oncology Research : POR
|
October 1, 2021
Significant Regional Differences in Lung Cancer Incidence in Hungary: Epidemiological Study Between 2011 and 2016
Gabriella Gálffy, Aladár Vastag, Krisztina Bogos, et al.
The New England Journal of Medicine
|
October 23, 2023
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
John V Heymach, David Harpole, Tetsuya Mitsudomi, et al.
Frontiers in Oncology
|
December 12, 2022
Underlying reasons for post-mortem diagnosed lung cancer cases - A robust retrospective comparative study from Hungary (HULC study)
Zolta N Kiss, Krisztina Bogos, Lilla Tamási, et al.
The New England Journal of Medicine
|
September 9, 2017
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Scott J Antonia, Augusto Villegas, Davey Daniel, et al.
Frontiers in Oncology
|
October 16, 2024
Revising cancer incidence in a Central European country: a Hungarian nationwide study between 2011-2019 based on a health insurance fund database
Zoltán Kiss, Tamás G Szabó, Csaba Polgár, et al.
Frontiers in Oncology
|
April 18, 2025
Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011-2019 based on a health insurance fund database
Zoltán Kiss, Anikó Maráz, György Rokszin, et al.
The New England Journal of Medicine
|
October 4, 2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J Antonia, Augusto Villegas, Davey Daniel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 27, 2019
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
Taofeek K Owonikoko, Huifeng Niu, Kristiaan Nackaerts, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
Lung Cancer (Amsterdam, Netherlands)
|
January 2, 2021
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
Filippo de Marinis, Konstantin K Laktionov, Artem Poltoratskiy, et al.
Pathology Oncology Research : POR
|
January 10, 2022
Increase in the Length of Lung Cancer Patient Pathway Before First-Line Therapy: A 6-Year Nationwide Analysis From Hungary
Zoltan Kiss, Krisztina Bogos, Lilla Tamási, et al.
Pathology Oncology Research : POR
|
October 1, 2021
Significant Regional Differences in Lung Cancer Incidence in Hungary: Epidemiological Study Between 2011 and 2016
Gabriella Gálffy, Aladár Vastag, Krisztina Bogos, et al.
The New England Journal of Medicine
|
October 23, 2023
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
John V Heymach, David Harpole, Tetsuya Mitsudomi, et al.
Frontiers in Oncology
|
December 12, 2022
Underlying reasons for post-mortem diagnosed lung cancer cases - A robust retrospective comparative study from Hungary (HULC study)
Zolta N Kiss, Krisztina Bogos, Lilla Tamási, et al.
The New England Journal of Medicine
|
September 9, 2017
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Scott J Antonia, Augusto Villegas, Davey Daniel, et al.
Frontiers in Oncology
|
October 16, 2024
Revising cancer incidence in a Central European country: a Hungarian nationwide study between 2011-2019 based on a health insurance fund database
Zoltán Kiss, Tamás G Szabó, Csaba Polgár, et al.
Frontiers in Oncology
|
April 18, 2025
Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011-2019 based on a health insurance fund database
Zoltán Kiss, Anikó Maráz, György Rokszin, et al.
The New England Journal of Medicine
|
October 4, 2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J Antonia, Augusto Villegas, Davey Daniel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 27, 2019
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
Taofeek K Owonikoko, Huifeng Niu, Kristiaan Nackaerts, et al.
Page
of 6